Biopharmaceuticals & Peptides

Pfēnex Expression Technology

Try the Next Generation in Microbial Expression Technology.
Pfēnex Expression Technology™, a Pseudomonas-based system, enables customers to express their recombinant protein or peptide reliably and cost-effectively.

This technology can:

• Increase protein expression
• Secrete proteins to the periplasmic space
• Maintain solubility
• Increase downstream yield
• Scale up easily
• Address protease issues
• Improve activity characteristics
• Lower cost of goods

In developing Pfēnex Expression Technology, Dowpharma continues to invest a significant amount of research and development in identifying high-performing strains of Pseudomonas fluorescens and further improving them through the application of sophisticated genomics tools. Dowpharma can quickly modify expression strains to increase the yield of a customer’s biotherapeutic. Pfēnex Expression Technology can help overcome some of the limitations of other bacterial expression systems, like disulfide bond formation, protease degradation of product and product secretion to the cellular periplasmic space to give you the highest possible product yield out of a microbial expression system.

A Scaleable Solution for your Peptide
If your therapeutic is a long peptide of more than 20 amino acids, requiring more than one kilo per year at commercial scale, Pfēnex Expression Technology can provide you with a cost-effective alternative to traditional synthetic methods. If you have been satisfying your current clinical needs with solid phase synthesized material, it's time to think about what the best manufacturing alternative for the long term could be. Pfēnex Expression Technology could be that alternative.

Developed to Meet Regulatory Requirements
Pfēnex Expression Technology has been developed with regulatory requirements in mind, specifically eliminating the need for antibiotics for plasmid stability, while also avoiding animal-derived products using a defined medium. By improving expression and meeting regulatory expectations while reducing costs, we can help our customers increase the number of products that are commercially viable and which ultimately go to market. Find out more in our regulatory summary. (113KB PDF)

In developing Pfēnex Expression Technology, Dowpharma^SM continues to invest a significant amount of research and development in identifying high-performing strains of Pseudomonas fluorescens, gene mapping these strains and improving them by application of sophisticated genomic tools. Dowpharma can quickly and easily modify the strains to increase the expression of a particular customer’s biotherapeutic.

Options for Working with Pfēnex Expression Technology
Dowpharma offers you a variety of ways to take advantage of this powerful technology:

• Initial feasibility study
• Process Development
• Pre-clinical and clinical manufacturing
• Pfēnex Expression Technology out-licensing

To discuss the best option for you, contact us.

To learn more about Pfēnex Expression Technology see:

• Pseudomonas fluorescens – a robust and high yield platform for Protein/Peptide production (2.8MB PDF)
• Pseudomonas fluorescens FAQ (129KB PDF)
• Pseudomonas fluorescens – Regulatory (113KB PDF)
• Use of pyrF to Stack Multiple Deletions in Pseudomonas fluorescens and to Stabilize Protein Production Plasmids with Antibiotic Resistance Markers – Regulatory (368KB PDF)

Pfēnex Expression Technology is based on novel strains of Pseudomonas fluorescens: Gram-negative microorganism Obligate aerobe Nonpathogenic (BL-1) This new technology is supported by advanced know-how and technologies: Genome fully sequenced by Dow Advanced bioinformatics and functional genomics capability Reliable strain and manufacturing process development No animal-derived products or antibiotics used in manufacturing or strain development Can be used with standard equipment Enabling rapid development of a robust manufacturing process: Rapid development of high yielding manufacturing programs Fermentor yields exceeding 15 grams per liter

In order to view some information you may need to download Adobe Reader.

®™^* Trademark of The Dow Chemical Company ("Dow") or an affiliated company of Dow
^SMService mark of The Dow Chemical Company